INREGEN has a total of 73 patent applications. It decreased the IP activity by 22.0%. Its first patent ever was published in 2009. It filed its patents most often in Australia, Republic of Korea and Japan. Its main competitors in its focus markets pharmaceuticals, biotechnology and medical technology are INTERCYTEX LTD, Healios Kk and YANAGA HIROKO.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 23 | |
#2 | Republic of Korea | 14 | |
#3 | Japan | 8 | |
#4 | United States | 8 | |
#5 | EPO (European Patent Office) | 7 | |
#6 | Taiwan | 4 | |
#7 | Canada | 3 | |
#8 | Hong Kong | 2 | |
#9 | New Zealand | 2 | |
#10 | China | 1 | |
#11 | Hungary | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Medical technology | |
#4 | Measurement | |
#5 | Macromolecular chemistry and polymers | |
#6 | Surface technology and coating |
# | Name | Total Patents |
---|---|---|
#1 | Basu Joydeep | 52 |
#2 | Jain Deepak | 37 |
#3 | Knight Oluwatoyin A | 36 |
#4 | Payne Richard | 36 |
#5 | Jayo Manuel J | 35 |
#6 | Ludlow John W | 33 |
#7 | Ilagan Roger M | 29 |
#8 | Kelley Russell W | 26 |
#9 | Bertram Timothy A | 26 |
#10 | Guthrie Kelly I | 25 |
Publication | Filing date | Title |
---|---|---|
US2018055885A1 | Bioactive renal cells for the treatment of chronic kidney disease | |
AU2015261636A1 | Cell-scaffold constructs | |
KR20200113287A | Renal cell populations and uses thereof | |
TW201304787A | Therapeutic formulations | |
KR20180027604A | Bioactive renal cells | |
EP3388509A1 | Isolated renal cells and uses thereof | |
CA3037457A1 | Cell-scaffold constructs | |
KR20190067267A | Cell-scaffold constructs |